176 related articles for article (PubMed ID: 9704171)
1. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
Head J; Ben-Shlomo Y; Lees AJ
Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
[No Abstract] [Full Text] [Related]
2. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
3. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
[TBL] [Abstract][Full Text] [Related]
4. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
5. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
6. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
7. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
8. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
9. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
Clarke CE
Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease.
Clarke CE; Moore AP
Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
[No Abstract] [Full Text] [Related]
11. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
Ben-Shlomo Y; Lees A;
Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
[No Abstract] [Full Text] [Related]
12. Deprenyl, excess mortality, and epidemiological traps.
Riggs JE
Clin Neuropharmacol; 1997 Jun; 20(3):276-8. PubMed ID: 9197952
[TBL] [Abstract][Full Text] [Related]
13. Clinical inquiries. What is the best initial treatment of Parkinson's disease?
Schreck J; Kelsberg G; Rich J; Ward R
J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387
[No Abstract] [Full Text] [Related]
14. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
[TBL] [Abstract][Full Text] [Related]
15. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
16. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
[TBL] [Abstract][Full Text] [Related]
17. Malignant melanoma in early Parkinson's disease: the DATATOP trial.
Constantinescu R; Romer M; Kieburtz K;
Mov Disord; 2007 Apr; 22(5):720-2. PubMed ID: 17373726
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
19. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
[TBL] [Abstract][Full Text] [Related]
20. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
Counsell C
BMJ; 1998 Dec; 317(7172):1586. PubMed ID: 9836669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
